4.5 Article

Label-free electrochemical immunosensor based on Nile blue A-reduced graphene oxide nanocomposites for carcinoembryonic antigen detection

Journal

ANALYTICAL BIOCHEMISTRY
Volume 500, Issue -, Pages 80-87

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ab.2016.02.010

Keywords

Label-free immunosensor; Redox probe; Au nanoparticles; Reduced graphene oxide; Carcinoembryonic antigen

Funding

  1. National Natural Science Foundation of China [51302117, 51303073, 51463008]
  2. Ganpo Outstanding Talents 555 Projects
  3. Training Plan for the Main Subject of Academic Leaders of Jiangxi Province
  4. Natural Science Foundation of Jiangxi Province [20151BAB203018, 20142BAB206028, 20142BAB216029]
  5. Jiangxi Provincial Department of Education [GJJ11590, GJJ13258]
  6. Postdoctoral Science Foundation of China [2014M551857, 2015T80688]
  7. Postdoctoral Science Foundation of Jiangxi Province [2014KY14]
  8. Science and Technology Landing Plan of Universities in Jiangxi Province [KJLD12081]

Ask authors/readers for more resources

In this article, a novel, label-free, and inherent electroactive redox immunosensor for carcinoembryonic antigen (CEA) based on gold nanoparticles (AuNPs) and Nile blue A (NB) hybridized electrochemically reduced graphene oxide (NB-ERGO) is proposed. The composite of NB-graphene oxide (NB-GO) was prepared by pi-pi stacking interaction. Then, chronoamperometry was adopted to simultaneously reduce HAuCl4 and nanocomposites of NB-GO for synthesizing AuNPs/NB-ERGO. The immunosensor was fabricated by capturing CEA antibody (anti-CEA) at this nanocomposite modified electrode. The immunosensor determination was based on the fact that, due to the formation of antigen-antibody immunocomplex, the decreased response currents of NB were directly proportional to the concentrations of CEA. Under optimal conditions, the linear range of the proposed immunosensor was estimated to be from 0.001 to 40 ng ml(-1) and the detection limit was estimated to be 0.00045 ng ml(-1). The proposed immunosensor was used to determine CEA in clinical serum samples with satisfactory results. The proposed method may provide promising potential application in clinical immunoassays with the properties of facile procedure, stability, high sensitivity, and selectivity. (C) 2016 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available